Saw Palmetto For Benign Prostatic Hyperplasia
| Effect |
None |
| Values |
Decrease of -0.16ng/dL but insignificant. |
| Trial Design |
Randomized trial |
| Trial Length |
6+ Months |
| Number of Subjects |
225 |
| Gender |
Male |
| Age Range |
45-64, 65+ |
Notes for this study:
320mg daily saw palmetto extract in patients with moderate to severe BPH saw no statistically significant change in AUASI scores, peak urinary flow rate, or secondary measures after 12 months of treatment. Side effects between placebo and saw palmetto were similar.
Funding issues for this study:
None
The Effect Of Increasing Doses Of Saw Palmetto Fruit Extract On Serum Prostate Specific Antigen: Analysis Of The CAMUS Randomized Trial
| Effect |
None |
| Values |
PSA rose 0.16ng/mL in the saw palmetto group over the course of the study, and 0.23ng/mL in the placebo group; an insignificant difference. |
| Trial Design |
Randomized trial |
| Trial Length |
6+ Months |
| Number of Subjects |
369 |
| Gender |
Male |
| Age Range |
45-64, 65+ |
Notes for this study:
Men over 45 years of age with AUA symptom score between 8 and 24 were randomly assigned to placebo or escalating doses of saw palmetto, which consisted of 320mg for first 24 weeks, 640mg for next 24 weeks, and 960mg for the final 24 weeks, for a total of 72 weeks. Serum PSA levels were measured with no difference between the saw palmetto group and placebo at any of the time points.
Funding issues for this study:
Manufacturer donated saw palmetto and matching placebo, but had no role in funding or design otherwise
Observational Database Serenoa Repens (DOSSER): Overview, Analysis And Results. A Multicentric SIUrO (Italian Society Of Oncological Urology) Project
| Effect |
Decrease |
| Trial Design |
Cohort |
| Trial Length |
1-6 months |
| Number of Subjects |
226 |
| Gender |
Male |
| Age Range |
45-64, 65+ |
Notes for this study:
In a retrospective analysis of subjects with benign prostatic hyperplasia using saw palmetto (320mg of a lipidosterolic extract) either alone or with an alpha-blocker noted that both groups experienced benefits to PSA concentrations (decrease) and urinary complications (urinary flow and void) with no noticeable affect on their sex lives as assessed by IIEF-5.
Effect Of Increasing Doses Of Saw Palmetto Extract On Lower Urinary Tract Symptoms: A Randomized Trial
| Effect |
None |
| Values |
PSA rose on average by 0.32ng/mL in the saw palmetto group and dropped -0.19ng/mL in the placebo group. The 1-sided difference between groups was not significant. |
| Trial Design |
Randomized trial |
| Trial Length |
6+ Months |
| Number of Subjects |
369 |
| Gender |
Male |
| Age Range |
45-64, 65+ |
Notes for this study:
Men over 45 years of age with AUA symptom score between 8 and 24 were randomly assigned to placebo or escalating doses of saw palmetto, which consisted of 320mg for first 24 weeks, 640mg for next 24 weeks, and 960mg for the final 24 weeks, for a total of 72 weeks. Serum PSA levels were measured with no difference between the saw palmetto group and placebo at any of the time points. Mean AUASI score decreased significantly over the course of the study in both placebo and saw palmetto groups (14.42 to 12.22 for saw palmetto, 14.69 to 11.70 for placebo), with no statistically significant difference between them. Many additional secondary measure were taken, including AUASI QoL, objective and subjective urinary flow measures, and sexual function measures. All were not significantly different between placebo and saw palmetto.
Funding issues for this study:
Manufacturer donated saw palmetto and matching placebo, but had no role in funding or design otherwise
